Abstract
Spinocerebellar ataxia type 34 (SCA34) is a dominantly inherited disease that causes late-onset ataxia, in association with skin lesions in the form of erythrokeratodermia variabilis. It is caused by mutations in the ELOVL4 gene, which encodes for the ELOVL4 protein and has the function of lengthening very long chain (VLC) fatty acids (FA), which are important components of central myelin. The aim of this work was to review the medical literature on the biochemical abnormalities of SCA34, and based on the obtained information, to propose supplementation of deficient FAs. A review of the ad hoc medical literature was performed. Plasma levels of the ELOVL4 products C32, C34 and C36 FA have not been reported in SCA34 yet. However, pathogenic variants of ELOVL4 revealed deficient biosynthesis of C28, C30, C32, C34 and C36 FA compared to WT in cell cultures, and the levels of ceramides and phosphatidylcholines containing ≥ 34 C FA were decreased compared to WT in HeLa cells expressing mutant SCA34 proteins. Besides, a pathological study of SCA34 revealed myelin destruction and loss of oligodendrocytes in cerebral and cerebellar white matter. Levels of VLC-FA should be determined, to identify specifically deficient FAs in SCA34. Cerebellar ataxia could possibly be improved by administration of the deficient FAs, as found in SCA38 with supplementation of docosahexaenoic acid. The authors suggest investigators with access to SCA34, to take into consideration this therapeutic hypothesis, and try to verify the potential efficacy of administration of VLCFA in this disease.
Similar content being viewed by others
Data Availability
No datasets were generated or analysed during the current study.
References
Beaudin M, Sellami L, Martel C, Touzel-Deschênes L, Houle G, Martineau L, et al. Characterization of the phenotype with cognitive impairment and protein mislocalization in SCA34. Neurol Genet. 2020;6:e403.
Ozaki K, Doi H, Mitsui J, Sato N, Iikuni Y, Majima T, et al. A novel mutation in ELOVL4 leading to spinocerebellar ataxia (SCA) with the hot cross bun sign but lacking erythrokeratodermia: a broadened spectrum of SCA34. JAMA Neurol. 2015;72:797–805.
Gyening YK, Chauhan NK, Tytanic M, Ea V, Brush RS, Agbaga MP. ELOVL4 mutations that cause spinocerebellar ataxia-34 differentially alter very long chain fatty acid biosynthesis. J Lipid Res. 2023;64:100317.
Gyening YK, Boris K, Cyril M, Brush RS, Nassogne MC, Agbaga MP. A novel ELOVL4 variant, L168S, causes early childhood-onset spinocerebellar ataxia-34 and retinal dysfunction: a case report. Acta Neuropathol Commun. 2023;11:131.
Cadieux-Dion M, Turcotte-Gauthier M, Noreau A, Martin C, Meloche C, Gravel M, et al. Expanding the clinical phenotype associated with ELOVL4 mutation: study of a large french-canadian family with autosomal dominant spinocerebellar ataxia and erythrokeratodermia. JAMA Neurol. 2014;71:470–5.
Bourassa CV, Raskin S, Serafini S, Teive HA, Dion PA, Rouleau GA. A new ELOVL4 mutation in a case of spinocerebellar ataxia with erythrokeratodermia. JAMA Neurol. 2015;72:942–3.
Tamura Y, Sassa T, Nishizawa T, Kihara A. Incomplete elongation of ultra-long-chain polyunsaturated Acyl-CoAs by the fatty acid elongase ELOVL4 in spinocerebellar ataxia type 34. Mol Cell Biol. 2023;43:1–17.
Nishide M, Le Marquand K, Davis MR, Halmágyi GM, Fellner A, Narayanan RK, et al. Two new families and a literature review of ELOVL4-associated spinocerebellar ataxia type 34. Cerebellum. 2024;23:268–77.
Xiao C, Binkley EM, Rexach J, Knight-Johnson A, Khemani P, Fogel BL, et al. A family with spinocerebellar ataxia and retinitis pigmentosa attributed to an ELOVL4 mutation. Neurol Genet. 2019;5:e357.
Ozaki K, Irioka T, Uchihara T, Yamada A, Nakamura A, Majima T, et al. Neuropathology of SCA34 showing widespread oligodendroglial pathology with vacuolar white matter degeneration: a case study. Acta Neuropathol Commun. 2021;9:172.
Manes M, Alberici A, Di Gregorio E, Boccone L, Premi E, Mitro N, et al. Docosahexaenoic acid is a beneficial replacement treatment for spinocerebellar ataxia 38. Ann Neurol. 2017;82:615–21.
Manes M, Alberici A, Di Gregorio E, Boccone L, Premi E, Mitro N, et al. Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: an open label extension study. Parkinsonism Relat Disord. 2019;63:191–4.
Gazulla J, Orduna-Hospital E, Benavente I, Rodríguez-Valle A, Osorio-Caicedo P, Alvarez-de Andrés S, et al. Contributions to the study of spinocerebellar ataxia type 38 (SCA38). J Neurol. 2020;267:2288–95.
Gazulla J, Benavente I, García-González E, Berciano J. Two-year follow-up of docosahexaenoic acid supplementation in spinocerebellar ataxia type 38 (SCA38). J Neurol. 2022;269:5643–6.
Funding
No institutional, private or corporate financial support financed this study.
Author information
Authors and Affiliations
Contributions
JG and JB have made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data.JG and JB have been involved in drafting the manuscript or revising it critically for important intellectual content.JG and JB gave final approval to the version to be published.
Corresponding author
Ethics declarations
Ethical Approval
in accordance with the local institutional ethics committee.
Consent for Publication
Not applicable.
Authorship
The listed authors qualify for authorship according to the following criteria.
-
1.
Have made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data.
-
2.
Been involved in drafting the manuscript or revising it critically for important intellectual content.
-
3.
Given final approval to the version to be published.
-
4.
Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Competing Interests
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Gazulla, J., Berciano, J. Potential Clinical Benefit of Very Long Chain Fatty Acid Supplementation in Spinocerebellar Ataxia Type 34. Cerebellum (2024). https://doi.org/10.1007/s12311-024-01705-x
Accepted:
Published:
DOI: https://doi.org/10.1007/s12311-024-01705-x